ReviewJournal of thoracic disease2017
Acute rejection.
Review in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Knowledge structure and academic influence in lung transplantation: a systematically bibliometric analysis of highly cited documents and multi-perspective extensive review.Journal of thoracic disease · 2026Article
- The Myeloid-T Lymphocyte Axis in Chronic Lung Allograft Rejection: Emerging Insights into the Immune Circuitry Driving Fibrosis.Results and problems in cell differentiation · 2026Review
- The Role of Microbiology at the 1-Month Surveillance Bronchoalveolar Lavage in the Identification of Complications in the First Year After Lung-Transplantation-A Retrospective Single-Center Experience.Life (Basel, Switzerland) · 2025Article
- Thirty years of lung transplantation: development of postoperative outcome and survival over three decades.Journal of thoracic disease · 2024Article
- Airway epithelium in lung transplantation: a potential actor for post-transplant complications?European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Lung transplantation in children.Turk gogus kalp damar cerrahisi dergisi · 2024Review
- Immunopathology of lung transplantation: from infection to rejection and vice versa.Frontiers in immunology · 2024Review
- Gene expression profiling in PBMCs for acute rejection in lung transplant recipients reveals myeloid responses.Frontiers in transplantation · 2024Article
- Role of Complement-dependent Cytotoxicity Crossmatch and HLA Typing in Solid Organ Transplant.Reviews on recent clinical trials · 2024Review
- Effect of β-Nicotinamide Adenine Dinucleotide on Acute Allograft Rejection After Rat Lung Transplantation.Transplantation direct · 2023Article
- Microcirculatory Disease in Patients after Heart Transplantation.Journal of clinical medicine · 2023Review
- Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation.Frontiers in pharmacology · 2023Article
- Surviving White-out: How to Manage Severe Noninfectious Acute Lung Allograft Dysfunction of Unknown Etiology.Transplantation direct · 2022Article
- Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Lymphocytic Airway Inflammation in Lung Allografts.Frontiers in immunology · 2022Review
- Prevention of vascular-allograft rejection by protecting the endothelial glycocalyx with immunosuppressive polymers.Nature biomedical engineering · 2021Article
- Circulating growth differentiation factor-15 as a novel biomarker in heart transplant.ESC heart failure · 2021Article
- The Actualization of the Transplantation Complex on the Axis of Psychosomatic Totality-Results of a Qualitative Study.Healthcare (Basel, Switzerland) · 2021Article
- [Fibrotic remodeling of the lung following lung and stem-cell transplantation].Der Pathologe · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite induction immunosuppression and the use of aggressive maintenance immunosuppressive regimens, acute allograft rejection following lung transplantation is still a problem with important diagnostic and therapeutic challenges. As well as causing early graft loss and mortality, acute rejection also initiates the chronic alloimmune responses and airway-centred inflammation that predispose to bronchiolitis obliterans syndrome (BOS), also known as chronic lung allograft dysfunction (CLAD), which is a major source of morbidity and mortality after lung transplantation. Cellular responses to human leukocyte antigens (HLAs) on the allograft have traditionally been considered the main mechanism of acute rejection, but the influence of humoral immunity is increasingly recognised. As with other several other solid organ transplants, antibody-mediated rejection (AMR) is now a well-accepted and distinct clinical entity in lung transplantation. While acute cellular rejection (ACR) has defined histopathological criteria, transbronchial biopsy is less useful in AMR and its diagnosis is complicated by challenges in the measurement of antibodies directed against donor HLA, and a determination of their significance. Increasing awareness of the importance of non-HLA antigens further clouds this issue. Here, we review the pathophysiology, diagnosis, clinical presentation and treatment of ACR and AMR in lung transplantation, and discuss future potential biomarkers of both processes that may forward our understanding of these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.